NexgenRx Statistics
Total Valuation
NexgenRx has a market cap or net worth of 15.19 million. The enterprise value is 15.39 million.
| Market Cap | 15.19M |
| Enterprise Value | 15.39M |
Important Dates
The last earnings date was Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | Apr 25, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.98% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 44.38M |
Valuation Ratios
The trailing PE ratio is 80.65.
| PE Ratio | 80.65 |
| Forward PE | n/a |
| PS Ratio | 1.27 |
| PB Ratio | 2.53 |
| P/TBV Ratio | 7.61 |
| P/FCF Ratio | 16.58 |
| P/OCF Ratio | 15.71 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.47, with an EV/FCF ratio of 16.80.
| EV / Earnings | 81.70 |
| EV / Sales | 1.32 |
| EV / EBITDA | 12.47 |
| EV / EBIT | 44.30 |
| EV / FCF | 16.80 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.09 |
| Quick Ratio | 0.13 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.27 |
| Debt / FCF | 0.38 |
| Interest Coverage | 7.29 |
Financial Efficiency
Return on equity (ROE) is 3.06% and return on invested capital (ROIC) is 3.43%.
| Return on Equity (ROE) | 3.06% |
| Return on Assets (ROA) | 0.98% |
| Return on Invested Capital (ROIC) | 3.43% |
| Return on Capital Employed (ROCE) | 5.65% |
| Revenue Per Employee | 596,247 |
| Profits Per Employee | 9,420 |
| Employee Count | 20 |
| Asset Turnover | 0.53 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.53 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.20 |
| Relative Strength Index (RSI) | 59.16 |
| Average Volume (20 Days) | 2,450 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NexgenRx had revenue of 11.92 million and earned 188,404 in profits. Earnings per share was 0.00.
| Revenue | 11.92M |
| Gross Profit | 9.25M |
| Operating Income | 355,122 |
| Pretax Income | 207,228 |
| Net Income | 188,404 |
| EBITDA | 1.20M |
| EBIT | 355,122 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 1.37 million in cash and 346,826 in debt, giving a net cash position of 1.02 million.
| Cash & Cash Equivalents | 1.37M |
| Total Debt | 346,826 |
| Net Cash | 1.02M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.00M |
| Book Value Per Share | 0.07 |
| Working Capital | 1.62M |
Cash Flow
In the last 12 months, operating cash flow was 967,270 and capital expenditures -50,935, giving a free cash flow of 916,335.
| Operating Cash Flow | 967,270 |
| Capital Expenditures | -50,935 |
| Free Cash Flow | 916,335 |
| FCF Per Share | n/a |
Margins
Gross margin is 77.58%, with operating and profit margins of 2.98% and 1.58%.
| Gross Margin | 77.58% |
| Operating Margin | 2.98% |
| Pretax Margin | 1.74% |
| Profit Margin | 1.58% |
| EBITDA Margin | 10.09% |
| EBIT Margin | 2.98% |
| FCF Margin | 7.68% |
Dividends & Yields
This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 3.57%.
| Dividend Per Share | 0.01 |
| Dividend Yield | 3.57% |
| Dividend Growth (YoY) | -5.19% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 481.26% |
| Buyback Yield | -0.98% |
| Shareholder Yield | 2.59% |
| Earnings Yield | 1.24% |
| FCF Yield | 6.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NexgenRx has an Altman Z-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1 |
| Piotroski F-Score | n/a |